Immunome’s (IMNM) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Immunome (NASDAQ:IMNM) in a research note published on Thursday,Benzinga reports. They currently have a $33.00 price objective on the stock.

Several other research firms have also recently commented on IMNM. Guggenheim cut their price objective on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday. Stephens reissued an “overweight” rating and set a $30.00 price target on shares of Immunome in a research report on Thursday. Finally, Lifesci Capital began coverage on shares of Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $25.50.

Immunome Trading Up 1.1 %

IMNM opened at $8.66 on Thursday. The stock has a market capitalization of $690.87 million, a P/E ratio of -1.07 and a beta of 1.93. Immunome has a 12 month low of $8.30 and a 12 month high of $26.70. The firm’s fifty day simple moving average is $9.80 and its 200 day simple moving average is $11.62.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The company had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, equities research analysts predict that Immunome will post -2.21 EPS for the current fiscal year.

Insider Transactions at Immunome

In other news, CEO Clay B. Siegall acquired 150,000 shares of the stock in a transaction dated Friday, January 31st. The shares were bought at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in shares of Immunome during the 4th quarter worth about $70,000. KLP Kapitalforvaltning AS acquired a new position in shares of Immunome during the 4th quarter worth about $75,000. AlphaQuest LLC increased its stake in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after purchasing an additional 7,129 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new position in Immunome in the 4th quarter valued at about $95,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.